Navigation Links
Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting

eoside HCV polymerase inhibitor HCV-796.

In Addition, Schering-Plough has initiated the HCV SPRINT-1 study (HCV Serine Protease Inhibitor Therapy-1), a large Phase II study with boceprevir ongoing at sites across the U.S., Canada and Europe. The primary objective of the study is to evaluate the safety and efficacy of boceprevir (800 mg TID) in combination with PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily) in the HCV genotype 1 treatment-naive patient population. The first part of the study (screening cohort 1) has completed enrollment and involves more than 500 patients in five treatment arms. A second part to the study (screening cohort 2) recently opened for patient enrollment and adds two additional treatment arms. This second cohort will evaluate the safety and efficacy of boceprevir in combination with PEGINTRON and a lower dose of REBETOL (400-1000 mg daily). In total, approximately 550-600 patients will be enrolled in the HCV SPRINT-1 study.

Schering-Plough also is conducting a large Phase II study evaluating the safety and efficacy of boceprevir in combination with PEGINTRON and REBETOL in patients chronically infected with HCV genotype 1 who were null responders to previous peginterferon and ribavirin combination therapy (i.e., patients who did not achieve undetectable HCV-RNA or a 2 log decline in viral load with a minimum of 12 weeks of peginterferon and ribavirin combination therapy). This represents a very difficult-to-treat patient population for which there is a great unmet medical need. The study involves approximately 350 patients and is ongoing at centers in the United States and Europe. All study participants have completed treatment with boceprevir in combination with PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily) and are in the follow-up phase of the study. Data from this study will be available later in 2007, and will help guide future clinical development of boceprevir.

Key Oral Pre
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:8/29/2014)... 2014 Research and Markets has ... Therapeutics Market & Pipeline Insight 2014" report to ... to prevent and eradicate the prevalence of cancer have ... confined to low specificity, safety and large number of ... a better solution. It has been discovered that peptides ...
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... Md., Aug. 30 Sequella, Inc., a clinical-stage ... life-threatening infectious diseases, announced today the restatement of ... of Maryland, Baltimore (UMB), concerning certain technology related ... patent (U.S. 6,663,846), jointly owned by Sequella and ...
... Aug. 30 Millennium Laboratories , a leading ... and staff treating chronic pain, announced today the appointment ... capacity as COO, Mr. Cohen is responsible for new ... business. He also has oversight of Millennium,s legislative initiatives ...
Cached Medicine Technology:Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 2Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology 3Millennium Laboratories Announces New Chief Operating Officer David Cohen 2
(Date:8/29/2014)... Los Angeles, CA (PRWEB) August 29, 2014 ... both the expert knowledge and authenticity of its doctors. ... ensures that only the most renowned doctors in their ... also helps to assure patients have a direct link ... Patients and doctors will be able to communicate ...
(Date:8/29/2014)... 29, 2014 Panic attacks are extremely ... feeling of intense stress and fear, which appears with ... sufferer, causing insecurity and affecting relationships. , A panic ... are many symptoms that patients can deal with. Anxiety, ... symptoms. Overcoming panic attacks is extremely important for sufferers, ...
(Date:8/29/2014)... Daily Gossip indicates in its recently published ... perfectly understand what patients have to go through at the ... creator of this new method. Bakker is a naturopathic doctor ... , Bakker claims that during all this time he ... living with the yeast infection can be. , Read ...
(Date:8/29/2014)... 30, 2014 Developed as a nod ... quality Canada Goose products offer the mobility, ... on Arctic runways. The company’s Canada Goose Chilliwack ... the current market. Additionally, the firm has unveiled its ... , At present, all high quality Chilliwack bombers ...
(Date:8/29/2014)... August 29, 2014 As reported by CNN.com ... (8/15), the process of admitting that you need help ... The article acknowledges and highlights the fact that if you ... may be very overwhelmed by all of the information that ... impossible to sift through, it is still possible to get ...
Breaking Medicine News(10 mins):Health News:Cosmetic Town Now Advocates for the Rights of Cosmetic Patients Using Novel Approach 2Health News:60 Second Panic Solution Review Exposes Simple Panic Attacks Remedy 2Health News:Candida Crusher Review Reveals a Unique Way to Eliminate Yeast Infection Permanently 2Health News:New Designs Of Canada Goose Chilliwack Bombers From DoudouneCanadienneGoosePasCher.fr 2Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3
... BOSTON Postmenopausal women who reported having used nonsteroidal ... time of enrollment in the Women,s Health Initiative study ... compared with women who reported no use of these ... 10th AACR International Conference on Frontiers in Cancer Prevention ...
... Institute (HCI) at the University of Utah have discovered a ... to new tools for predicting which breast cancers will spread ... spread. Their results are published online today in the journal ... for breast cancer studies, the researchers grafted tumor tissue from ...
... working night shifts may be compromising their own health ... Dr. Joan Tranmer told the Canadian Cardiovascular Congress 2011, ... Canadian Cardiovascular Society. Dr. Tranmer,s study investigated the ... disease in female hospital employees who worked both shift ...
... By Randy Dotinga HealthDay Reporter , FRIDAY, Oct. ... staple of professional ice hockey games, but are they as ... punches thrown during National Hockey League games end in significant ... isn,t particularly dangerous, possibly because it,s hard to get traction ...
... known as the PSA test, is valuable in predicting which ... diagnosed with low-risk prostate cancer, a Mayo Clinic study has ... the North Central Section of the American Urological Association ( ... decision to use the PSA test is best made by ...
... that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans ... tool in prostate cancer. The results of three studies, ... Section of the American Urological Association ( http://www.ncsaua.org/default.aspx ), ... of C-11 choline PET scans. One study ...
Cached Medicine News:Health News:NSAID use associated with lower colorectal cancer mortality rates among postmenopausal women 2Health News:Will my breast cancer spread? Discovery may predict probability of metastasis 2Health News:Female shift workers may be at higher risk of heart disease 2Health News:Female shift workers may be at higher risk of heart disease 3Health News:Hockey Fistfights Rarely Cause Injuries, Study Claims 2Health News:Hockey Fistfights Rarely Cause Injuries, Study Claims 3Health News:Mayo Clinic study: PSA test valuable in predicting biopsy need, low-risk prostate cancer 2Health News:Trio of studies support use of PET/CT scans as prostate cancer staging tool 2
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
Medicine Products: